Endogenous GLP-1 is rapidly degraded by the enzyme Dipeptidyl Peptidase-4 (DPP-4) , with an effective plasma half-life of only ~2 minutes after intravenous injection ( [39] ) ( [40] )
Expanding the Reach of GLP-1RAs: Potential Applications in Psoriasis, AD, HS, and Chronic Wounds Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer benefits well beyond weight loss and diabetes management, with emerging evidence suggesting potential roles in the treatment of psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and chronic wounds, according to a new literature review in Pharmaceutics.
This means they are not subject to the same rigorous pre-market safety and efficacy testing required of licensed pharmaceutical products
Interestingly, recent data have demonstrated the importance of FA availability and composition of the tumor microenvironment in the ability of cancer cells to execute the ferroptotic program [33]
Provides systemic healing support and anti-inflammatory effects